enVVeno Medical Corporation (NASDAQ:NVNO) Short Interest Up 24.7% in February

enVVeno Medical Corporation (NASDAQ:NVNO) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 532,700 shares, a growth of 24.7% from the February 13th total of 427,100 shares. Based on an average trading volume of 135,100 shares, the short-interest ratio is presently 3.9 days. Approximately 3.1% of the company’s stock are sold short.

Institutional Trading of enVVeno Medical

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in enVVeno Medical during the fourth quarter valued at about $816,000. Westside Investment Management Inc. grew its position in enVVeno Medical by 132.0% during the fourth quarter. Westside Investment Management Inc. now owns 205,025 shares of the company’s stock valued at $619,000 after buying an additional 116,650 shares during the period. Corsair Capital Management L.P. bought a new position in enVVeno Medical during the third quarter valued at about $390,000. Maven Securities LTD bought a new position in enVVeno Medical during the third quarter valued at about $295,000. Finally, Hohimer Wealth Management LLC bought a new position in enVVeno Medical during the third quarter valued at about $286,000. Institutional investors own 34.71% of the company’s stock.

enVVeno Medical Stock Up 1.7 %

NVNO traded up $0.05 during trading on Monday, hitting $2.96. 55,079 shares of the company’s stock were exchanged, compared to its average volume of 107,579. The business’s 50 day moving average is $3.26 and its two-hundred day moving average is $3.50. enVVeno Medical has a fifty-two week low of $2.45 and a fifty-two week high of $6.48. The stock has a market cap of $51.91 million, a P/E ratio of -2.29 and a beta of 1.38.

enVVeno Medical (NASDAQ:NVNO) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05. On average, sell-side analysts forecast that enVVeno Medical will post -1.32 earnings per share for the current year.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).